share_log

Arcutis Biotherapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Watanabe Todd Franklin

SEC announcement ·  Mar 7 06:15
Summary by Futu AI
Todd Franklin Watanabe, associated with Arcutis Biotherapeutics, completed a sale of 14,903 shares of common stock on March 4, 2024. The transaction was executed at a price of $11.1212 per share, resulting in a total sale value of approximately $165,739.24. Following the sale, Watanabe directly holds 874,533 shares of the company. Additionally, Watanabe has indirect ownership of 231,140 shares through trusts and an LLC. The sale was conducted in the open market.
Todd Franklin Watanabe, associated with Arcutis Biotherapeutics, completed a sale of 14,903 shares of common stock on March 4, 2024. The transaction was executed at a price of $11.1212 per share, resulting in a total sale value of approximately $165,739.24. Following the sale, Watanabe directly holds 874,533 shares of the company. Additionally, Watanabe has indirect ownership of 231,140 shares through trusts and an LLC. The sale was conducted in the open market.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.